Cingulate Inc. (CING)

Market Cap	3.84M
Revenue (ttm)	n/a
Net Income (ttm)	-23.53M
Shares Out	3.98M
EPS (ttm)	-26.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	164,810
Open	1.140
Previous Close	1.110
Day's Range	0.910 - 1.150
52-Week Range	0.750 - 23.400
Beta	-0.96
Analysts	Buy
Price Target	8.00 (+729.36%)
Earnings Date	May 14, 2024

About CING

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headqua...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2021
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: CING

Analyst Forecast

According to 3 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 729.36% from the latest price.

Price Target

$8.0

(729.36% upside)

Analyst Consensus: Buy